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feasibility and tolerability in a cohort of volunteers. HFPV 
was applied in patients eligible for breast 3DRT, lung 
stereotactic RT, locally-advanced lung RT. Durations of 
breath hold obtained under HFPV for each clinical situation 
were reported. Dosimetric parameters in free breathing (FB), 
MI gating, or HFPV conditions were compared. The HFPV was 
also adapted and tested for thoracic MRI and PET. 
 
Results: For volunteers, HFPV offered a mean duration time 
for apnea like breath hold of 10.6 minutes. Transferred in 
patients, this percussion assisted radiotherapy (PART) was 
applied with good tolerance in the first 3 patients without 
treatment breaks during the overall fractionated RT. All 
together, 50 RT fractions have been delivered under PART, 
and the mean duration of apnea-like breath hold necessary 
for “beam on” was 7.61 minutes (SD 2.3). HFPV offered a 
favorable dosimetric profile when compared to MI or FB for 
these 3 clinical RT situations (table). In addition, the HFPV 
markedly improved both PET and MRI image quality in 
detecting small pulmonary lesions (figure).  
 
Conclusion: the HPFV allowed prolonged apnea-like breath 
hold that could be used both for fractionated RT and chest 
imaging. These preliminary results were very promising and 
prompt to develop larger studies to evaluate its 
reproducibility and potential clinical benefits both for 
radiotherapy and for lung PET/MRI imaging. 
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Purpose or Objective: Moving away from guideline-based 
treatment to a more personalized approach requires accurate 
outcome prediction. Yet, physicians’ predictions of survival 
and toxicity after lung radiotherapy are as good as flipping a 
coin (Oberije et al.,Radiother. Oncol. 2014). We hypothesize 
that the physicians’ knowledge of complex interactions 
between clinical variables and treatment outcomes is a 
valuable resource for prediction modelling. Therefore, we 
created and compared expert-based and data-driven 
prediction models. The predicted endpoints are severe 
dyspnea (CTCAE dyspnea scores ≥ 2) and increases in the 
CTCAE dyspnea score after radiotherapy (RT). Severe dyspnea 
occurs in approximately 15% of all patients treated with lung 
radiotherapy and has a possibly severe impact on patients’ 
quality of life. 
 
Material and Methods: Data from 1152 lung cancer patients 
treated in clinical routine (2006-2015, partially incomplete 
data) were used. Seven experts selected causal links between 
19 variables (patient, disease, treatment, and dose-related 
variables) and post-RT dyspnea to construct Bayesian 
Networks (BNs). Their individual choices, the consensus 
choices, and a data-driven algorithm were used to build BNs 
for both endpoints. 80% of the data were used for model 
building. Validation was performed for all models in terms of 
discrimination (Area under the Curve) in the remaining 20% of 
the data, isolated before modelling. 
 
Results: Expert-based networks were more complex than 
algorithmically-constructed networks (range: 7-30 vs. 3-6 
arcs) but their predictions for severe dyspnea in non-dyspneic 
patients were not significantly better (see 95% confidence 
intervals in table). Furthermore, all models besides expert 
model 6 were not different from chance as AUC confidence 
intervals include 0.5. Models predicting increases in CTCAE 
dyspnea scores performed better (all models’ AUCs > 0.6) and 
different from 0.5 with 97.5% confidence. Among those, the 
data-driven approach performed significantly better than 3 of 
the 7 expert models. Consensus networks between experts 
did not improve the predictive performance. 
 
 
 
 
 
Conclusion: The results suggest that reliable predictions of 
post-RT dyspnea scores ≥ 2 in non-dyspneic patients are not 
achievable with any of the presented models. Clinical routine 
appears to still miss appropriate biomarkers. In contrast, 
prediction modelling for post-RT increases in dyspnea is 
feasible with expert knowledge as well as data-driven 
algorithms. The comparison between expert- and data-driven 
modelling indicates that data-driven modelling can yield 
simpler models with similar performance as expert-driven 
modelling. 
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Purpose or Objective: The role of thoracic radiotherapy 
(TRT) in extensive stage small-cell lung cancer (ES-SCLC) has 
been evaluated in a recent phase 3 randomised control trial. 
The results of the Chest Radiotherapy Extensive stage Small 
cell lung cancer Trial (CREST) were published in the Lancet 
(2015,385,36-42). This study showed that TRT did not 
significantly improve 1-year overall survival, which was the 
primary endpoint. However there was a significant 
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improvement in 2-year overall survival, suggesting TRT should 
be considered for all patients with ES-SCLC who respond to 
chemotherapy. An additional analysis showed that in patients 
with a response but residual disease after chemotherapy, the 
difference in 1-year survival was significantly better after 
TRT (Lancet 2015,385,1292-3). We carried out a European 
survey to determine the impact of the publication on clinical 
practice. 
 
Material and Methods: In May 2015 an electronic 
questionnaire of 34 items was composed using Select Survey 
software designed for running online surveys. Questions 
covered the use of TRT before and after the CREST study, 
evaluated the current practice of prophylactic cranial 
irradiation (PCI), including dose and fractionation, and asked 
whether practice was restricted based on performance status 
(PS) and age. The survey was distributed by email to one 
thoracic clinical/radiation oncologist per centre in 7 
European countries. A reminder was sent to non-responders. 
 
Results: This European-wide survey received 95 complete 
responses (UK n=42, Belgium n=23, Netherlands n=14, France 
n=8, Switzerland n=5, Germany n=2, Poland n=1). A response 
rate of 74% was achieved within the UK. Before the 
publication of the CREST study only 25% of centres were 
giving TRT routinely to patients who had responded to 
chemotherapy, compared to the current practice of 81%. 
Currently the preferred dose and fractionation of TRT is 30 
Gy in 10 fractions in 70% of centres, however a wide variety 
of fractionations were used before the CREST publication. An 
upper limit of PS ECOG 2 is commonly applied to TRT (83 %). 
In the 18 centres (19%) not implementing TRT there were a 
wide variety of explanations with no single reason standing 
out. Regarding the practice of PCI in ES-SCLC, 96% of centres 
give PCI routinely if patients have responded to 
chemotherapy. Of these, 52% deliver 25Gy in 10 fractions and 
44% deliver 20Gy in 5 fractions. An upper age limit was 
applied in 76% of all centres, the most common age limit 
being 75 (60 %). An upper limit for PS was applied in 88% of 
all centres, most commonly ECOG 2. 
 
Conclusion: Following the publication of the CREST study 
there has been a dramatic increase in the use of TRT in 
patients with ES-SCLC who have responded to chemotherapy. 
The dose and fractionation schedule used in the study has 
widely been adopted as standard practice across Europe. 
There is also evidence of high consistency in European 
practice in the use of PCI in patients with ES-SCLC. 
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Purpose or Objective: To compare acute skin toxicity 
between prone whole-breast irradiation (WBI) with a 
sequential boost (SeqB) and a simultaneous integrated boost 
(SIB). 
 
Materials and Methods: 167 patients were randomized 
between WBI with a SeqB or a SIB. 150 patients were treated 
at Ghent University Hospital (UZ Gent) and 17 at Liège 
University Hospital. All patients were treated in prone 
position to 40.05 Gy in 15 fractions to the whole breast. In 
the SeqB arm a median dose of 10 Gy in 4 fractions (negative 
surgical margins) or 14.88 Gy in 6 fractions (transsection) was 
prescribed to the PTV_boost (CTV to PTV margin of 5 mm). In 
the SIB arm a median dose of 46.8 or 49.95 Gy (negative and 
positive surgical margins, respectively) was prescribed to the 
CTV_boost with dose decay to 40.05 Gy in the first 2 cm 
around the CTV_boost. In the SeqB arm dose parameters 
were calculated on the summed plan (WBI + boost). For 
comparison, a PTV_optim was created including the PTV for 
WBI more than 2 cm away from the CTV_boost as illustrated 
in Figure 1.  
 
 
 
Dermatitis was scored using the Common Toxicity Criteria for 
Adverse Events (CTCAE). Desquamation was scored as: none, 
dry or moist; pruritus as absent or present.  
 
Results: The analysis of dose parameters was done on 146 
patients treated at UZ Gent. Reasons for excluding patients 
were electron boost (2), 3 different plans on 3 different CTs 
(1) and changed treatment arm due to machine breakdown 
(1). This latter patient was excluded from the toxicity 
analysis as well. Patient age was the only significantly 
different parameter between treatment arms (mean age 59.6 
± 11.0 vs 55.7 ± 10.4 years, p=0.0210). Dose coverage of the 
CTV_boost was slightly better in the control arm (D95 of 98 ± 
1% vs 97 ± 2%, p<0.01). The volume of the PTV_optim and the 
skin receiving more than 105% of the prescription dose were 
significantly higher in the SeqB-arm than in the SIB-arm (27 ± 
20% vs 9 ± 6% for the PTV_optim and 394 ± 216cc vs 201 ± 
125cc for the skin, both p<0.01).In both arms, 6/83 patients 
developed moist desquamation (primary endpoint). Grade 
2/3 dermatitis was significantly more frequent in the SeqB 
arm (38/83 vs 24/83 patients, p=0.037). In the SIB and SeqB 
arm, respectively, 36 and 51 patients developed pruritus 
(p=0.015). The incidence of edema was lower in the SIB arm 
(59 vs 68 patients), but not statistically significant (p=0.071). 
 
Conclusion: Acute toxicity is not increased using a SIB in 
prone hypofractionated WBI. In contrast, grade 2/3 
dermatitis and pruritus are significantly less frequent. With 
our SIB-technique, high dose regions outside the boost region 
are smaller than with a SeqB. 
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